Bayer

Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

University of Pittsburgh, Bayer form research alliance

Wednesday, January 11, 2017

The University of Pittsburgh and Bayer have established a master collaboration agreement to advance research for heart, lung and blood disease indications. This broad collaboration spans from early research studies, to drug development and big data analysis including real-world evidence studies. In addition to the research partnership, Bayer will be supporting an independent investigator-initiated clinical trial in sickle cell disease.

[Read More]

Recursion wins award for drug discovery platform

Monday, December 26, 2016

Recursion Pharmaceuticals announced that it has won two Fierce Innovation awards from the biotech and pharmaceutical industries today for its innovative platform. The awards, “Best Biotech Innovation” and “Best In Show—New Product or Service,” recognize Recursion’s disruptive combination of experimental biology and artificial intelligence applied to drug discovery.

[Read More]

FDA accepts Bayer’s sBLA for myBETAapp and BETACONNECT Navigator

Thursday, December 15, 2016

Bayer has announced that the FDA has accepted the filing of a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECTNavigator. MyBETAapp is intended for patients taking BETASERON (interferon beta-1b), to help them record their treatment information such as drug injections and injection sites. The BETACONNECT Navigator is a tool that enables healthcare professionals the ability to review injection history for their patients.

[Read More]